Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no head-to-head or comparative effectiveness research studies available evaluating responses to biologics in CCP+ patients in a real-world setting. The aim of this study was to compare the effectiveness of abatacept vs a TNF inhibitor (TNFi) in patients with RA who are CCP+.
Results: The 330 pairs of propensity score-matched abatacept and TNFi initiators had no substantial differences in baseline characteristics. Both treatment groups had similar mean change in CDAI at 6 months as well as achievement of LDA, remission and mACR20/50/70 responses (Table). Among the 97 matched biologic-naïve pairs, there was no significant difference in change in CDAI for abatacept initiators vs TNFi initiators (p=0.19). However, in the 233 matched biologic-experienced pairs, those initiating abatacept had a greater improvement in mean change in CDAI (p=0.033) and were more likely to achieve an mACR50 response (p=0.014).
Conclusion: Patients with RA who were CCP+ and received either abatacept or TNFi had a substantial improvement in clinical disease activity. In the overall propensity score-matched sample, similar outcomes were observed for both treatment groups. However, analysis of the biologic-experienced cohort found that abatacept initiators had a greater improvement in disease activity than TNFi initiators.
1. Sokolove J, et al. Ann Rheum Dis 2016;75:709–14.
2. Harrold LR, et al. Ann Rheum Dis 2016;75(Suppl 2):505–6.
Original abstract © EULAR/BMJ. First presented at EULAR 2017 and published in Ann Rheum Dis 2017;76 (Suppl 2):AB0408. Any reprints, promotional options, education material etc have to be done through the original source (ARD/BMJ).
To cite this abstract in AMA style:Harrold LR, Litman HJ, Connolly S, Alemao E, Price K, Kelly S, Rebello S, Hua W, Kremer J. Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/comparative-effectiveness-of-abatacept-versus-tnfi-in-patients-with-ra-who-are-ccp-in-the-united-states-corrona-registry/. Accessed June 3, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-effectiveness-of-abatacept-versus-tnfi-in-patients-with-ra-who-are-ccp-in-the-united-states-corrona-registry/